Senior team members at RM Global have advised on and completed the following transactions and assignments:
Equity investment in Elastagen’s Series B and Strategic Collaboration with Elastagen
Advised Amorepacific on the foregoing transaction
Series B Financing
Advised Kahr Medical on the foregoing transaction
Strategic investment and Distribution Agreement
Advised Cosmotec on the foregoing transaction
Series B Preferred Stock Financing
Advised Checkpoint Surgical on the foregoing transaction
Global Licensing Agreement Cardiovascular Device Platform
Advised Distal Access on the foregoing transaction
Series A Financing
Advised Distal Access on the foregoing transaction
Strategic Advisory Services
Advised Riverain Technologies on the foregoing transaction
Strategic Collaboration with Novartis to Screen & Develop Israel-Sourced Novel Drug Candidates
Advised BioLineRx on the foregoing transaction
Equity investment in Tria Beauty’s series D and Strategic Collaboration with Tria Beauty
Advised Amore Pacific on the foregoing transaction
Equity investment in Brickell Bio’s Series A and Strategic Collaboration with Brickell Bio
Advised Amore Pacific on the foregoing transaction
Equity investment in Neothetics (formerly “Lithera”) Series C and Strategic Collaboration with Neothetics
Advised Amore Pacific on the foregoing transaction
Strategic consulting & execution
Advised PacificPharma on the foregoing transaction